174 related articles for article (PubMed ID: 22229312)
1. Anti-cocaine vaccine based on coupling a cocaine analog to a disrupted adenovirus.
Koob G; Hicks MJ; Wee S; Rosenberg JB; De BP; Kaminsky SM; Moreno A; Janda KD; Crystal RG
CNS Neurol Disord Drug Targets; 2011 Dec; 10(8):899-904. PubMed ID: 22229312
[TBL] [Abstract][Full Text] [Related]
2. Disrupted adenovirus-based vaccines against small addictive molecules circumvent anti-adenovirus immunity.
De BP; Pagovich OE; Hicks MJ; Rosenberg JB; Moreno AY; Janda KD; Koob GF; Worgall S; Kaminsky SM; Sondhi D; Crystal RG
Hum Gene Ther; 2013 Jan; 24(1):58-66. PubMed ID: 23140508
[TBL] [Abstract][Full Text] [Related]
3. Cocaine vaccine dAd5GNE protects against moderate daily and high-dose "binge" cocaine use.
Havlicek DF; Rosenberg JB; De BP; Hicks MJ; Sondhi D; Kaminsky SM; Crystal RG
PLoS One; 2020; 15(11):e0239780. PubMed ID: 33253224
[TBL] [Abstract][Full Text] [Related]
4. Cocaine analog coupled to disrupted adenovirus: a vaccine strategy to evoke high-titer immunity against addictive drugs.
Hicks MJ; De BP; Rosenberg JB; Davidson JT; Moreno AY; Janda KD; Wee S; Koob GF; Hackett NR; Kaminsky SM; Worgall S; Toth M; Mezey JG; Crystal RG
Mol Ther; 2011 Mar; 19(3):612-9. PubMed ID: 21206484
[TBL] [Abstract][Full Text] [Related]
5. Adenovirus capsid-based anti-cocaine vaccine prevents cocaine from binding to the nonhuman primate CNS dopamine transporter.
Maoz A; Hicks MJ; Vallabhjosula S; Synan M; Kothari PJ; Dyke JP; Ballon DJ; Kaminsky SM; De BP; Rosenberg JB; Martinez D; Koob GF; Janda KD; Crystal RG
Neuropsychopharmacology; 2013 Oct; 38(11):2170-8. PubMed ID: 23660705
[TBL] [Abstract][Full Text] [Related]
6. Novel cocaine vaccine linked to a disrupted adenovirus gene transfer vector blocks cocaine psychostimulant and reinforcing effects.
Wee S; Hicks MJ; De BP; Rosenberg JB; Moreno AY; Kaminsky SM; Janda KD; Crystal RG; Koob GF
Neuropsychopharmacology; 2012 Apr; 37(5):1083-91. PubMed ID: 21918504
[TBL] [Abstract][Full Text] [Related]
7. Fate of systemically administered cocaine in nonhuman primates treated with the dAd5GNE anticocaine vaccine.
Hicks MJ; Kaminsky SM; De BP; Rosenberg JB; Evans SM; Foltin RW; Andrenyak DM; Moody DE; Koob GF; Janda KD; Ricart Arbona RJ; Lepherd ML; Crystal RG
Hum Gene Ther Clin Dev; 2014 Mar; 25(1):40-9. PubMed ID: 24649839
[TBL] [Abstract][Full Text] [Related]
8. AAVrh.10-mediated expression of an anti-cocaine antibody mediates persistent passive immunization that suppresses cocaine-induced behavior.
Rosenberg JB; Hicks MJ; De BP; Pagovich O; Frenk E; Janda KD; Wee S; Koob GF; Hackett NR; Kaminsky SM; Worgall S; Tignor N; Mezey JG; Crystal RG
Hum Gene Ther; 2012 May; 23(5):451-9. PubMed ID: 22486244
[TBL] [Abstract][Full Text] [Related]
9. Ethical issues in using a cocaine vaccine to treat and prevent cocaine abuse and dependence.
Hall W; Carter L
J Med Ethics; 2004 Aug; 30(4):337-40. PubMed ID: 15289512
[TBL] [Abstract][Full Text] [Related]
10. Anti-cocaine vaccines: antibody protection against relapse.
Kantak KM
Expert Opin Pharmacother; 2003 Feb; 4(2):213-8. PubMed ID: 12562311
[TBL] [Abstract][Full Text] [Related]
11. Peripheral cocaine-blocking agents: new medications for cocaine dependence. An introduction to immunological and enzymatic approaches to treating cocaine dependence reported by Fox, Gorelick and Cohen in the immediately succeeding articles (see pages 153-174).
Sparenborg S; Vocci F; Zukin S
Drug Alcohol Depend; 1997 Dec; 48(3):149-51. PubMed ID: 9449012
[No Abstract] [Full Text] [Related]
12. Efficacy of an adenovirus-based anti-cocaine vaccine to reduce cocaine self-administration and reacqusition using a choice procedure in rhesus macaques.
Evans SM; Foltin RW; Hicks MJ; Rosenberg JB; De BP; Janda KD; Kaminsky SM; Crystal RG
Pharmacol Biochem Behav; 2016; 150-151():76-86. PubMed ID: 27697554
[TBL] [Abstract][Full Text] [Related]
13. Development of a therapeutic vaccine for the treatment of cocaine addiction.
Fox BS
Drug Alcohol Depend; 1997 Dec; 48(3):153-8. PubMed ID: 9449013
[TBL] [Abstract][Full Text] [Related]
14. Investigations into the efficacy of multi-component cocaine vaccines.
Kimishima A; Olson ME; Janda KD
Bioorg Med Chem Lett; 2018 Sep; 28(16):2779-2783. PubMed ID: 29317163
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model.
Kantak KM; Collins SL; Lipman EG; Bond J; Giovanoni K; Fox BS
Psychopharmacology (Berl); 2000 Feb; 148(3):251-62. PubMed ID: 10755738
[TBL] [Abstract][Full Text] [Related]
16. Time course of changes in cocaine self-administration behavior in rats during immunization with the cocaine vaccine IPC-1010.
Kantak KM; Collins SL; Bond J; Fox BS
Psychopharmacology (Berl); 2001 Jan; 153(3):334-40. PubMed ID: 11271406
[TBL] [Abstract][Full Text] [Related]
17. Predicting the clinical efficacy and potential adverse effects of a humanized anticocaine monoclonal antibody.
Norman AB; Ball WJ
Immunotherapy; 2012 Mar; 4(3):335-43. PubMed ID: 22401638
[TBL] [Abstract][Full Text] [Related]
18. Immunization for prevention and treatment of cocaine abuse: legal and ethical implications.
Cohen PJ
Drug Alcohol Depend; 1997 Dec; 48(3):167-74. PubMed ID: 9449015
[TBL] [Abstract][Full Text] [Related]
19. Vaccines for cocaine abuse.
Orson FM; Kinsey BM; Singh RA; Wu Y; Kosten TR
Hum Vaccin; 2009 Apr; 5(4):194-9. PubMed ID: 19276665
[TBL] [Abstract][Full Text] [Related]
20. The future potential for cocaine vaccines.
Orson FM; Wang R; Brimijoin S; Kinsey BM; Singh RA; Ramakrishnan M; Wang HY; Kosten TR
Expert Opin Biol Ther; 2014 Sep; 14(9):1271-83. PubMed ID: 24835496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
